Sanara MedTech Inc. cash flow to debt ratio of 14.08% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Sanara MedTech Inc.'s free cash flow has increased -953.86% from $-253.08K last year to $2.16M, signaling increasing performance

Sanara MedTech Inc.'s debt to equity ratio is 6.88, which means that the company's assets are unhealthy financed, signaling financial risk.

Sanara MedTech Inc.'s debt has increased relative to shareholder equity from 0.82 last year to 6.88 today, signaling weakened financials

Sanara MedTech Inc. has a net debt to EBITDA ratio of 3.50x, which exceeds the 3.00x threshold, indicating high leverage and potential financial risk

Sanara MedTech Inc.'s interest coverage ratio is 1.17, which means that the company struggles to meet interest obligations, signaling financial risk.

Sanara MedTech Inc.'s profit margin has decreased (180.08%) in the last year from -11.15% to -31.23%, signaling decreasing performance

Sanara MedTech Inc.'s short-term assets of $33.54M exceed its short-term liabilities of $18.63M

Sanara MedTech Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Sanara MedTech Inc.'s return on equity of -246.44%, is lower than 15.00%, indicating bad performance

Sanara MedTech Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Sanara MedTech Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Sanara MedTech Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Sanara MedTech Inc. has a free cash flow yield of 0.69%, which is below the 2.00% threshold, indicating limited cash return relative to market value

Sanara MedTech Inc.'s yearly earnings has decreased 288.66% since last year from $-9.66M to $-37.56M, signaling decreasing performance

Sanara MedTech Inc.'s yearly revenue has increased 18.97% since last year from $86.67M to $103.12M, signaling increasing performance

ROIC 15.14% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

Sanara MedTech Inc.'s 3-year revenue CAGR of 31.03% is positive, indicating growing revenue over the past 3 years

Sanara MedTech Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Sanara MedTech Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Sanara MedTech Inc. has insufficient data to evaluate this check.

Sanara MedTech Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Sanara MedTech Inc. is overvalued relative to its fair value price of 5.57 based on EBITDA multiple model

Sanara MedTech Inc. has an EV/EBITDA ratio of 38.38x, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings

Sanara MedTech Inc. is overvalued relative to its fair value price of -17.93 based on Earnings Fair Value model

Sanara MedTech Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Sanara MedTech Inc. has a price-to-book ratio of 42.48x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Sanara MedTech Inc. has a price-to-sales ratio of 2.77x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue